Zhang and co-workers report on the renoprotective role of the vitamin D receptor (VDR) in diabetic nephropathy using the method of streptozotocin-induced hyperglycemia in wild-type and VDR -/mice. Also, experiments with cultured mesangial cells and podocytes confirm the effect of the active vitamin D metabolite 1,25(OH) 2 D 3 on inhibition of the renin-angiotensin system (RAS) in vitro. The authors conclude that the higher activation of the intrarenal RAS is the key factor to induce more severe diabetic nephropathy in VDR -/mice.
Vitamin D is hydroxylated in the liver by 25-hydroxylase to 25-(OH) vitamin D. A second, subsequent hydroxylation in the proximal renal tubule by 1αhydroxylase is required to form the active metabolite 1,25(OH) 2 D 3 . The binding of 1,25(OH) 2 D 3 to its nuclear vitamin D receptor (VDR) leads to VDR activation and heterodimerization with the retinoid X receptor (RXR) and other cofactors, to form the VDR-RXR complex, which binds to the vitamin D response element of target genes to regulate gene transcription. The VDR has been found in many tissues-not only in the classical target organs, intestine, kidney, and bone, but also in different cell types, including the immune system; this suggests a role of vitamin D well beyond regulation of calcium. The vitamin D system is involved in regulating the immune system, cell growth, and differentiation (reviewed by Holick 1 ). For example, vitamin D supplementation in infancy is associated with a reduced risk of development of type 1 diabetes. Recently, renoprotective actions of active vitamin D metabolites were reported in an experimental setting of glomerulonephritis as well as in human chronic renal disease.
Role of vitamin D and the (intrarenal) renin-angiotensin system in diabetic and nondiabetic nephropathy
VDR -/mice express elevated angiotensin II plasma levels due to increased intrarenal renin activity. 2 Increased activity of the renin-angiotensin system (RAS) could also be demonstrated in vitamin Ddeficient wild-type mice, whereas treatment with 1,25(OH) 2 D 3 reduced renin activity. These studies demonstrate that the vitamin D system acts as a negative regulator of the intrarenal RAS by suppressing renin activity independently. 2 The reduced activity of the intrarenal RAS is considered to be an important factor in the renoprotective role of active vitamin D metabolites in experimental and human chronic kidney disease. Hyperglycemia induces intrarenal renin production and downregulates VDR and 1α-hydroxylase in proximal tubular cells. The combination of hyperglycemia and absence of the VDR is therefore expected to result in a further increase of the intrarenal RAS activity, as is elegantly demonstrated in vivo and in vitro in the study by Zhang et al. 3 (this issue). However, increased renin leads to higher systemic blood pressure, and, in fact, this was reported in the nondiabetic VDR -/mouse. 2 This might even be more pronounced in VDR -/mice with diabetes, resulting in additive disturbances of the systemic and renal vasculature, promoting glomerular changes, proteinuria, and interstitial fibrosis. However, a trend toward reduced blood pressure in the streptozotocintreated mice in the presence of significant hyperglycemia was reported. 4 Blood pressure in the diabetic VDR -/and wildtype mice was not reported in the study by Zhang et al. 3 With streptozotocin-induced diabetes in the mouse, proteinuria is observed after approximately 5 weeks. Because at this early time the most prominent histologic marker of diabetic nephropathy is glomerular hypertrophy, it seems likely that hemodynamic effects contribute to the development of early albuminuria, which is superimposed on the proteinuria observed in the nondiabetic VDR -/mouse. This assumption is in line with the clinical observation of elevated blood pressure in a substantial number of young patients with type 1 diabetes even in the absence of microalbuminuria. 5
Activation of the intrarenal reninangiotensin system and progression of chronic kidney disease?
Hyperglycemia itself induces proteinuria, and this is augmented by lack of activity of the vitamin D system. Proteinuria results in a decline of tubular megalin expression, resulting in lower endocytosis. This leads to decreased 25(OH)D 3 reabsorption and increased proteinuria. Endogenous 1,25(OH) 2 D 3 counterbalances the decline in megalin abundance and reduced 25(OH)D 3 uptake. 6 Hyperglycemia increases abundance and translocalization of protein kinase Cα (PKCα) in glomerular cells and, most prominently, in capillaries. Several effects of hyperglycemia are mediated by PKC activation, such as increased endothelial-cell permeability and stimulated expression of matrix proteins and metalloproteinases. 7 Angiotensin II is also known to stimulate PKC. An important effect of PKC stimulation is an increase in transforming growth factor-β (TGF-β), resulting in increased capillary permeability and fibrogenic activity. In addition, TGF-β is involved in myofibroblast activation of interstitial fibroblasts and tubular epithelial-to-mesenchymal transition, 8 co mmentar y an important event in the generation of α-smooth muscle actin-positive matrixproducing cells in the kidney, which promotes a fibrogenic process. Active vitamin D metabolites not only reduce intrarenal RAS activation but also suppress TGF-β activation indirectly via stimulation of the hepatocyte growth factor. Therefore, it is not surprising that nondiabetic VDR -/mice show increased proteinuria as compared with their wild-type littermates. The same mechanism can be proposed for the more pronounced proteinuria induced by hyperglycemia in the VDR -/mouse compared with the wild-type one, indicating more severe diabetic nephropathy. However, the amount of proteinuria that is indicative of glomerular disease in the mouse model has not been firmly established. 4 Reduced proteinuria with administration of 1,25(OH) 2 D 3 or its analogues was described in several experimental models of chronic kidney disease. In five-sixths subtotally nephrectomized rats, 1,25(OH) 2 D 3 significantly reduced proteinuria. 9 Furthermore, the 1,25(OH) 2 D 3 analogue 22-oxa-calcitriol not only reduced protein excretion but also inhibited glomerular hypertrophy and glomerulosclerosis (see below). In addition, there is clinical evidence that active vitamin D metabolites have antiproteinuric effects in human chronic kidney disease stages 3 and 4. In doubleblind, placebo-controlled studies, paricalcitol reduced proteinuria in about 50% of the patients, whereas in the placebo group this was observed in only 25%. 10
Effect of vitamin D and hyperglycemia on mesangial cells and on podocytes
Human diabetic nephropathy is histologically characterized by diffuse thickening of the glomerular basal membrane between the endothelium and the podocyte and by mesangial expansion. With progressing time, arteriolar hyalinosis and tubulointerstitial fibrosis develop. Mesangial cells express VDR. Treatment with 1,25(OH) 2 D 3 inhibited mesangialcell proliferation in vivo in experimental anti-Thy-1 glomerulonephritis. 11 Furthermore, reduced albuminuria and decreased glomerulosclerosis as well as reduced expression of fibrogenic markers were reported in this study. In the diabetic mouse model, the glomerular hypertrophy is followed by mesangial proliferation and mesangial sclerosis. In the latter two events, TGF-β plays a significant role in the pathogenesis.
In diabetic nephropathy, the initial glomerular alterations also affect the podocyte as an important cell for disease progression, especially with respect to development of proteinuria. In subtotally nephrectomized rats, podocyte hypertrophy could be prevented by concomitant 1,25(OH) 2 D 3 . 12 Also, markers of podocyte integrity as well as podocyte number could be preserved with 1,25(OH) 2 D 3 . In the study by Zhang et al., 3 podocin levels were measured to assess podocyte integrity. But podocin expression was not different in diabetic VDR -/mice compared with wild-type diabetic mice. On one hand, this indicates the absence of toxicity of the low-dose streptozotocin protocol used; on the other hand, the podocytes were not significantly affected by the hyperglycemia-induced hemodynamic or vitamin D-depleted effects. In view of the described increased glomerulosclerosis index in the diabetic VDR -/mouse, this is surprising, but it may be explained by the relative resistance to the development of glomerulosclerosis and renal failure 4 in the mouse strain used.
Summary
Experimental and clinical evidence is accumulating that indicates a renoprotective role of the vitamin D system in chronic renal disease, including diabetic nephropathy (Figure 1 ). Both hyperglycemia and the absence of the vitamin Ddependent signals stimulate the intrarenal activity of the RAS with elevated renin and angiotensin II levels. An important common pathway for the synergistic effect of hyperglycemia and inactivity of the vitamin D system is stimulation of TGF-β. In turn, TGF-β induces profibrotic events that result in interstitial fibrosis. Active vitamin D metabolites inhibit the activation of the RAS as well as the induction of the fibrotic cascade. Diabetic nephropathy is also characterized by glomerular changes, that is, glomerular tuft expansion and glomerulosclerosis. Experimental models of glomerulonephritis or subtotal nephrectomy as well as the study by Zhang et al. 3 suggest reduced podocyte injury and less mesangial proliferation co m m e nt a r y with the administration of active vitamin D metabolites. Reduced glomerular and tubulointerstitial alterations are accompanied by reduced proteinuria in experimental diabetic nephropathy and other experimental kidney disease. Reduced proteinuria with administration of active vitamin D was also confirmed in human subjects with chronic kidney disease. The reported increased susceptibility of the kidneys of VDR -/mice to hyperglycemia might hold not only for diabetic nephropathy, but also for other chronic kidney diseases. These findings all suggest that vitamin D deficiency should be avoided in diabetic and nondiabetic chronic kidney disease. However, the effect of (low) doses of active vitamin D metabolites on development of diabetic nephropathy in patients with diabetes should be evaluated in prospective randomized clinical trials.
